ALS: Canadian patients eligible for inclusion in U.S. clinical trials

Canadian patients with ALS are now eligible to enrol in a study testing a promising experimental treatment shown to halt or reverse disease progression over a six-month period.
Canadians with amyotrophic lateral sclerosis — a deadly neurodegenerative disease for which there is no effective treatment — can be enrolled at one site only, at the University of Massachusetts.
Bowing to pressure from Canadian patients, BrainStorm Cell Therapeutics revised its protocol for the adva